News Center
2022
- Categories:Milestones
- Author:
- Origin:
- Time of issue:2022-11-29 11:23
- Views:
(Summary description)In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
2022
(Summary description)In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
- Categories:Milestones
- Author:
- Origin:
- Time of issue:2022-11-29 11:23
- Views:
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
SAUNDERS
WRITE A MESSAGE TO US
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China Tel： 0756-8135888
©2021 Livzon 京ICP证000000号 Support：300.cn
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China
©2021 Livzon 京ICP证000000号
Support：300.cn